Total Payments
$90,060
2024 Payments
$525.00
Companies
8
Transactions
155
Medicare Patients
1,309
Medicare Billing
$181,745
Payment Breakdown by Category
Consulting$62,014 (68.9%)
Travel$18,418 (20.5%)
Other$6,600 (7.3%)
Food & Beverage$3,015 (3.3%)
Education$11.92 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $62,014 | 25 | 68.9% |
| Travel and Lodging | $18,418 | 71 | 20.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $6,600 | 2 | 7.3% |
| Food and Beverage | $3,015 | 56 | 3.3% |
| Education | $11.92 | 1 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| EISAI INC. | $67,482 | 121 | $0 (2022) |
| Exelixis Inc. | $9,451 | 18 | $0 (2019) |
| Novartis Pharmaceuticals Corporation | $7,063 | 7 | $0 (2018) |
| Genentech USA, Inc. | $3,989 | 5 | $0 (2017) |
| Bayer HealthCare Pharmaceuticals Inc. | $1,100 | 1 | $0 (2017) |
| AstraZeneca Pharmaceuticals LP | $525.00 | 1 | $0 (2024) |
| AstraZeneca UK Limited | $437.50 | 1 | $0 (2019) |
| Gilead Sciences, Inc. | $11.92 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $525.00 | 1 | AstraZeneca Pharmaceuticals LP ($525.00) |
| 2022 | $2,610 | 2 | EISAI INC. ($2,610) |
| 2021 | $3,252 | 3 | Eisai Inc. ($3,240) |
| 2020 | $1,620 | 2 | Eisai Inc. ($1,620) |
| 2019 | $17,141 | 33 | EISAI INC. ($12,192) |
| 2018 | $49,575 | 89 | Eisai Inc. ($37,572) |
| 2017 | $15,336 | 25 | Eisai Inc. ($10,248) |
All Payment Transactions
155 individual payment records from CMS Open Payments — Page 1 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/01/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Consulting Fee | Cash or cash equivalent | $525.00 | General |
| Category: Oncology | ||||||
| 11/04/2022 | EISAI INC. | Lenvima (Drug) | Consulting Fee | Cash or cash equivalent | $1,305.00 | General |
| Category: Oncology | ||||||
| 09/30/2022 | EISAI INC. | Lenvima (Drug) | Consulting Fee | Cash or cash equivalent | $1,305.00 | General |
| Category: Oncology | ||||||
| 11/01/2021 | Eisai Inc. | Lenvima (Drug) | Consulting Fee | Cash or cash equivalent | $1,620.00 | General |
| Category: Oncology | ||||||
| 06/01/2021 | Gilead Sciences, Inc. | — | Education | In-kind items and services | $11.92 | General |
| 03/29/2021 | Eisai Inc. | Lenvima (Drug) | Consulting Fee | Cash or cash equivalent | $1,620.00 | General |
| Category: Oncology | ||||||
| 06/08/2020 | Eisai Inc. | Lenvima (Drug) | Consulting Fee | Cash or cash equivalent | $1,350.00 | General |
| Category: Oncology | ||||||
| 06/08/2020 | Eisai Inc. | Lenvima (Drug) | Consulting Fee | Cash or cash equivalent | $270.00 | General |
| Category: Oncology | ||||||
| 12/09/2019 | EISAI INC. | Lenvima (Drug) | Consulting Fee | Cash or cash equivalent | $810.00 | General |
| Category: Oncology | ||||||
| 10/30/2019 | Exelixis Inc. | Cabometyx (Drug) | Travel and Lodging | In-kind items and services | $245.37 | General |
| Category: Oncology | ||||||
| 10/25/2019 | Exelixis Inc. | Cabometyx (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,300.00 | General |
| Category: Oncology | ||||||
| 10/25/2019 | Exelixis Inc. | Cabometyx (Drug) | Travel and Lodging | In-kind items and services | $235.26 | General |
| Category: Oncology | ||||||
| 10/25/2019 | Exelixis Inc. | Cabometyx (Drug) | Food and Beverage | In-kind items and services | $49.98 | General |
| Category: Oncology | ||||||
| 10/25/2019 | Exelixis Inc. | Cabometyx (Drug) | Food and Beverage | In-kind items and services | $49.98 | General |
| Category: Oncology | ||||||
| 10/25/2019 | Exelixis Inc. | Cabometyx (Drug) | Travel and Lodging | Cash or cash equivalent | $28.76 | General |
| Category: Oncology | ||||||
| 10/24/2019 | Exelixis Inc. | Cabometyx (Drug) | Food and Beverage | In-kind items and services | $154.53 | General |
| Category: Oncology | ||||||
| 10/24/2019 | Exelixis Inc. | Cabometyx (Drug) | Travel and Lodging | Cash or cash equivalent | $12.76 | General |
| Category: Oncology | ||||||
| 10/19/2019 | EISAI INC. | Lenvima (Drug) | Consulting Fee | Cash or cash equivalent | $3,470.00 | General |
| Category: Oncology | ||||||
| 10/19/2019 | EISAI INC. | Lenvima (Drug) | Travel and Lodging | Cash or cash equivalent | $454.60 | General |
| Category: Oncology | ||||||
| 10/19/2019 | EISAI INC. | Lenvima (Drug) | Travel and Lodging | Cash or cash equivalent | $199.40 | General |
| Category: Oncology | ||||||
| 10/19/2019 | EISAI INC. | Lenvima (Drug) | Travel and Lodging | Cash or cash equivalent | $76.00 | General |
| Category: Oncology | ||||||
| 10/19/2019 | EISAI INC. | Lenvima (Drug) | Travel and Lodging | Cash or cash equivalent | $65.00 | General |
| Category: Oncology | ||||||
| 10/19/2019 | EISAI INC. | Lenvima (Drug) | Food and Beverage | Cash or cash equivalent | $49.99 | General |
| Category: Oncology | ||||||
| 10/19/2019 | EISAI INC. | Lenvima (Drug) | Food and Beverage | Cash or cash equivalent | $49.99 | General |
| Category: Oncology | ||||||
| 10/19/2019 | EISAI INC. | Lenvima (Drug) | Food and Beverage | Cash or cash equivalent | $24.58 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 366 | 674 | $282,931 | $48,155 |
| 2022 | 5 | 295 | 623 | $236,435 | $41,907 |
| 2021 | 4 | 318 | 699 | $268,181 | $50,029 |
| 2020 | 4 | 330 | 758 | $276,046 | $41,655 |
Total Patients
1,309
Total Services
2,754
Medicare Billing
$181,745
Procedure Codes
20
All Medicare Procedures & Services
20 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 100 | 399 | $152,877 | $26,836 | 17.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 58 | 58 | $42,938 | $7,496 | 17.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 115 | 124 | $31,836 | $5,077 | 15.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 39 | 39 | $22,827 | $3,832 | 16.8% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 21 | 21 | $17,578 | $2,712 | 15.4% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 12 | 12 | $6,870 | $1,159 | 16.9% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Facility | 2023 | 21 | 21 | $8,005 | $1,044 | 13.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 104 | 420 | $158,344 | $28,663 | 18.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 109 | 121 | $30,678 | $4,936 | 16.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 29 | 29 | $21,108 | $3,981 | 18.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 31 | 31 | $18,011 | $3,132 | 17.4% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Facility | 2022 | 22 | 22 | $8,294 | $1,196 | 14.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 114 | 481 | $178,758 | $34,153 | 19.1% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 60 | 60 | $42,992 | $8,001 | 18.6% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 124 | 137 | $34,351 | $5,862 | 17.1% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Facility | 2021 | 20 | 21 | $12,080 | $2,013 | 16.7% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 129 | 546 | $198,849 | $30,415 | 15.3% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 49 | 49 | $34,356 | $5,810 | 16.9% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 128 | 139 | $34,087 | $4,224 | 12.4% |
| 99203 | New patient office or other outpatient visit, typically 30 minutes | Facility | 2020 | 24 | 24 | $8,754 | $1,206 | 13.8% |
About Dr. Mark Karwal, MD
Dr. Mark Karwal, MD is a Internal Medicine healthcare provider based in Iowa City, Iowa. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/14/2005. The National Provider Identifier (NPI) number assigned to this provider is 1891770616.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mark Karwal, MD has received a total of $90,060 in payments from pharmaceutical and medical device companies, with $525.00 received in 2024. These payments were reported across 155 transactions from 8 companies. The most common payment nature is "Consulting Fee" ($62,014).
As a Medicare-enrolled provider, Karwal has provided services to 1,309 Medicare beneficiaries, totaling 2,754 services with total Medicare billing of $181,745. Data is available for 4 years (2020–2023), covering 20 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Hematology & Oncology, Medical Oncology
- Location Iowa City, IA
- Active Since 12/14/2005
- Last Updated 05/04/2009
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1891770616
Products in Payments
- Lenvima (Drug) $67,482
- Cabometyx (Drug) $9,451
- KISQALI (Drug) $7,063
- Herceptin (Biological) $3,989
- Stivarga (Drug) $1,100
- IMFINZI (Biological) $525.00
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Iowa City
Steven Mickelsen, Md, MD
Internal Medicine — Payments: $2.4M
Internal Medicine $2.4M
Brian Olshansky, Md, MD
Internal Medicine — Payments: $495,150
Internal Medicine $495,150
Paul Rothman, Md, MD
Internal Medicine — Payments: $233,440
Internal Medicine $233,440
Udaya Kabadi, Md, MD
Internal Medicine — Payments: $197,995
Internal Medicine $197,995
Dr. Carla Nester, M.d, M.D
Internal Medicine — Payments: $135,680
Internal Medicine $135,680
Lawrence Hunsicker, Md, MD
Internal Medicine — Payments: $118,663
Internal Medicine $118,663